French drug maker Sanofi SA yesterday told employees of Genzyme Corp., the Cambridge company Sanofi acquired in April, that they will have a new reporting structure within the parent company.
Sanofi chief executive Christopher A. Viehbacher said earlier this year that Genzyme will retain its name and remain a standalone biotechnology unit within Sanofi.
But in an employee bulletin out yesterday, Sanofi said the Genzyme unit will be smaller and include only its personalized genetic health and multiple sclerosis operations.
